Universität zu Köln

Heidenreich, Axel, Paffenholz, Pia, Nestler, Tim, Tolkach, Yuri and Pfister, David (2021). Targeted Therapy in Patients with Metastatic Male Germ Cell Tumors. Urol.Int., 105 (7-8). S. 720 - 724. BASEL: KARGER. ISSN 1423-0399

Full text not available from this repository.

Abstract

Ten to fifteen percent of patients with metastatic testis cancer (mGCT) will develop chemorefractory disease of which about 50% will die. We report on the integration of next generation sequencing in daily clinical practice to identify druggable mutations in metastatic lesions of 3 patients with mGCT. Mutational analysis revealed KIT D820G, TP53, and NPM1 mutations as well as mismatch repair deficiency with loss of MSH2 and MSH6 proteins so that targeted therapy with sunitinib (n = 2) or pembrolizumab (n = 1) was initiated resulting in remarkable partial remissions for 9, 12+, and 15 months.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Heidenreich, Axel UNSPECIFIED UNSPECIFIED UNSPECIFIED Paffenholz, Pia UNSPECIFIED UNSPECIFIED UNSPECIFIED Nestler, Tim UNSPECIFIED UNSPECIFIED UNSPECIFIED Tolkach, Yuri UNSPECIFIED UNSPECIFIED UNSPECIFIED Pfister, David UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-579828
DOI:	10.1159/000510717
Journal or Publication Title:	Urol.Int.
Volume:	105
Number:	7-8
Page Range:	S. 720 - 724
Date:	2021
Publisher:	KARGER
Place of Publication:	BASEL
ISSN:	1423-0399
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language Urology & Nephrology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/57982